Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LLY Stock Forecast 2026-2027
$903.02
Current Price
$808.22B
Market Cap
Buy 24
Hold 6
Sell 1
Wall St Analyst Ratings
Distance to LLY Price Targets
+66.1%
To High Target of $1,500.00
+39.5%
To Median Target of $1,260.00
-5.9%
To Low Target of $850.00
LLY Price Momentum
-0.2%
1 Week Change
-0.4%
1 Month Change
+9.1%
1 Year Change
-16.0%
Year-to-Date Change
-20.4%
From 52W High of $1,133.95
+44.8%
From 52W Low of $623.78
📊 TOP ANALYST CALLS
Did LLY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Eli Lilly is one of their latest high-conviction picks.
Latest LLY Stock Price Targets & Analyst Predictions
Based on our analysis of 44 Wall Street analysts, LLY has a bullish consensus with a median price target of $1,260.00 (ranging from $850.00 to $1,500.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $903.02, the median forecast implies a 39.5% upside. This outlook is supported by 24 Buy, 6 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Peter Verdult at Citigroup, projecting a 66.1% upside. Conversely, the most conservative target is provided by Rajesh Kumar at HSBC, suggesting a 5.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LLY Analyst Ratings
24
Buy
6
Hold
1
Sell
LLY Price Target Range
Low
$850.00
Average
$1,260.00
High
$1,500.00
Current: $903.02
Latest LLY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LLY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $1,327.00 |
| Apr 2, 2026 | B of A Securities | Jason Gerberry | Buy | Maintains | $1,294.00 |
| Mar 30, 2026 | Guggenheim | Seamus Fernandez | Buy | Maintains | $1,163.00 |
| Mar 17, 2026 | HSBC | Rajesh Kumar | Reduce | Downgrade | $850.00 |
| Feb 25, 2026 | RBC Capital | Trung Huynh | Outperform | Initiates | $1,250.00 |
| Feb 20, 2026 | Barclays | Emily Field | Overweight | Initiates | $1,350.00 |
| Feb 10, 2026 | Freedom Broker | Buy | Upgrade | $N/A | |
| Feb 9, 2026 | Deutsche Bank | James Shin | Buy | Maintains | $1,285.00 |
| Feb 5, 2026 | JP Morgan | Chris Schott | Overweight | Maintains | $1,300.00 |
| Feb 5, 2026 | Cantor Fitzgerald | Carter Gould | Overweight | Maintains | $1,205.00 |
| Feb 5, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $1,313.00 |
| Feb 5, 2026 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $1,280.00 |
| Feb 2, 2026 | Freedom Broker | Hold | Maintains | $N/A | |
| Jan 20, 2026 | Guggenheim | Seamus Fernandez | Buy | Maintains | $1,161.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $1,250.00 |
| Dec 15, 2025 | B of A Securities | Tim Anderson | Buy | Maintains | $1,268.00 |
| Dec 10, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $1,200.00 |
| Dec 4, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $1,200.00 |
| Dec 3, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Nov 24, 2025 | Bernstein | Courtney Breen | Outperform | Maintains | $1,300.00 |
Eli Lilly and Company (LLY) Competitors
The following stocks are similar to Eli Lilly based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eli Lilly and Company (LLY) Financial Data
Eli Lilly and Company has a market capitalization of $808.22B with a P/E ratio of 40.4x. The company generates $65.18B in trailing twelve-month revenue with a 31.7% profit margin.
Revenue growth is +42.6% quarter-over-quarter, while maintaining an operating margin of +44.9% and return on equity of +101.2%.
Valuation Metrics
Market Cap
$808.22B
Enterprise Value
$864.82B
P/E Ratio
40.4x
PEG Ratio
0.8x
Price/Sales
12.8x
Growth & Margins
Revenue Growth (YoY)
+42.6%
Gross Margin
+82.5%
Operating Margin
+44.9%
Net Margin
+31.7%
EPS Growth
+50.5%
Financial Health
Cash/Price Ratio
+0.9%
Current Ratio
1.6x
Debt/Equity
165.3x
ROE
+101.2%
ROA
+19.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Eli Lilly and Company (LLY) Business Model
About Eli Lilly and Company
What They Do
Leading pharmaceutical company focused on innovative medicines.
Business Model
The company generates revenue through the discovery, development, manufacture, and sale of human pharmaceutical products. Its diverse portfolio includes treatments for various critical health needs, particularly in diabetes, oncology, and immunology, which are sold globally.
Additional Information
Founded in 1876 and headquartered in Indianapolis, Eli Lilly engages in initiatives to enhance access to medications in low- and middle-income countries. The company also invests in a robust research and development pipeline, focusing on late-stage projects aimed at non-communicable diseases.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50,000
CEO
Mr. David A. Ricks
Country
United States
IPO Year
1972
Website
www.lilly.comEli Lilly and Company (LLY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Eli Lilly (LLY) concluded the recent trading session at $903.02, signifying a -1.83% move from its prior day's close.
Apr 21, 2026
By Zacks Equity Research
Tale of the Tape
LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion
Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel in vivo CAR-T therapy for cancer.
Apr 21, 2026
By Zacks Equity Research
Analyst Blog
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q1 Results?
Novo Nordisk's Q1 performance hinges on Ozempic and Wegovy sales, but rising competition, pricing pressure and muted 2026 guidance may temper growth momentum.
Apr 20, 2026
By Ahan Chakraborty
Analyst Blog
Latest News
Quick Summary
Eli Lilly is acquiring Kelonia Therapeutics for $3.25 billion upfront, with a potential total cost of up to $7 billion.
Why It Matters
Eli Lilly's acquisition of Kelonia Therapeutics signals growth potential and strategic expansion in biotech, impacting stock valuation and future revenue streams.
Source: CNBC
Market Sentiment:
Positive
Quick Summary
CNBC reports on recent developments in the pharmaceuticals sector, highlighting key updates that may impact investors in the industry.
Why It Matters
Pharmaceutical news impacts stock valuations, regulatory outlooks, and market trends, influencing investment decisions in healthcare sectors.
Source: CNBC Television
Market Sentiment:
Positive
Quick Summary
Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront, enhancing its portfolio in next-generation cancer treatments.
Why It Matters
Eli Lilly's $7 billion acquisition of Kelonia Therapeutics enhances its cancer treatment portfolio, potentially leading to growth in revenue and market share, impacting stock performance positively.
Source: Invezz
Market Sentiment:
Positive
Quick Summary
Eli Lilly announced plans to acquire Kelonia Therapeutics for up to $7 billion to enhance its cancer treatment portfolio.
Why It Matters
Eli Lilly's acquisition of Kelonia Therapeutics signals a strong commitment to expanding its oncology portfolio, potentially driving future revenue growth and enhancing market competitiveness.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Eli Lilly (NYSE: LLY) will acquire Kelonia Therapeutics to enhance its genetic medicine capabilities, focusing on Kelonia's iGPS gene delivery platform for T-cell modification.
Why It Matters
Eli Lilly's acquisition of Kelonia Therapeutics enhances its genetic medicine capabilities, potentially accelerating innovation and revenue growth in a high-demand sector.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Eli Lilly's drug Foundayo shows over 40% growth recently, driven by the success of its GLP-1 drug portfolio.
Why It Matters
Eli Lilly's strong growth from Foundayo and GLP-1 drugs signals robust revenue potential, enhancing investor confidence and possibly driving stock value higher.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About LLY Stock
What is Eli Lilly and Company's (LLY) stock forecast for 2026?
Based on our analysis of 44 Wall Street analysts, Eli Lilly and Company (LLY) has a median price target of $1,260.00. The highest price target is $1,500.00 and the lowest is $850.00.
Is LLY stock a good investment in 2026?
According to current analyst ratings, LLY has 24 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $903.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LLY stock?
Wall Street analysts predict LLY stock could reach $1,260.00 in the next 12 months. This represents a 39.5% increase from the current price of $903.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eli Lilly and Company's business model?
The company generates revenue through the discovery, development, manufacture, and sale of human pharmaceutical products. Its diverse portfolio includes treatments for various critical health needs, particularly in diabetes, oncology, and immunology, which are sold globally.
What is the highest forecasted price for LLY Eli Lilly and Company?
The highest price target for LLY is $1,500.00 from Peter Verdult at Citigroup, which represents a 66.1% increase from the current price of $903.02.
What is the lowest forecasted price for LLY Eli Lilly and Company?
The lowest price target for LLY is $850.00 from Rajesh Kumar at HSBC, which represents a -5.9% decrease from the current price of $903.02.
What is the overall LLY consensus from analysts for Eli Lilly and Company?
The overall analyst consensus for LLY is bullish. Out of 44 Wall Street analysts, 24 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $1,260.00.
How accurate are LLY stock price projections?
Stock price projections, including those for Eli Lilly and Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 11:19 AM UTC